Study shows protein inhibitor as potential treatment approach for common mutations found in non-Hodgkin lymphomas

byUniversity of Texas M. D. Anderson Cancer CenterCancer cell during cell division. Credit: National Institutes of HealthA study at The University of Texas MD Anderson Cancer Center demonstrated

Updated on: December 22,2023

Study shows protein inhibitor as potential treatment approach for common mutations found in non-Hodgkin lymphomas

byUniversity of Texas M. D. Anderson Cancer CenterCancer cell during cell division. Credit: National Institutes of HealthA study at The University of Texas MD Anderson Cancer Center demonstrated

Updated on:December 22,2023

Survival in Primary Hemophagocytic Lymphohistiocytosis Can Be as High as 100%

February 2024Lara C. Pullen, PhDResults from a contemporary standard-of-care study of patients with primary hemophagocytic lymphohistiocytosis (pHLH) reveal that firstline etoposide-based therapy is m

Updated on: February 18,2024

Survival in Primary Hemophagocytic Lymphohistiocytosis Can Be as High as 100%

February 2024Lara C. Pullen, PhDResults from a contemporary standard-of-care study of patients with primary hemophagocytic lymphohistiocytosis (pHLH) reveal that firstline etoposide-based therapy is m

Updated on:February 18,2024

Researchers discover compound that fights leukemia and lymphoma

JANUARY 12, 2024byUniversity of Texas at El PasoRenato Aguilera, Ph.D., a professor in the Department of Biological Sciences at The University of Texas at El Paso, is the principal investigator

Updated on: March 28,2024

Researchers discover compound that fights leukemia and lymphoma

JANUARY 12, 2024byUniversity of Texas at El PasoRenato Aguilera, Ph.D., a professor in the Department of Biological Sciences at The University of Texas at El Paso, is the principal investigator

Updated on:March 28,2024

Residual cancer burden after neoadjuvant therapy can accurately predict breast cancer survival

byUniversity of Texas M. D. Anderson Cancer CenterW. Fraser Symmans, M.D. Credit: MD Anderson Cancer CenterResearchers from The University of Texas MD Anderson Cancer Center today reported resul

Updated on: December 22,2023

Residual cancer burden after neoadjuvant therapy can accurately predict breast cancer survival

byUniversity of Texas M. D. Anderson Cancer CenterW. Fraser Symmans, M.D. Credit: MD Anderson Cancer CenterResearchers from The University of Texas MD Anderson Cancer Center today reported resul

Updated on:December 22,2023

The Human Tumor Atlas Network: Mapping Cancer's Complexity and Evolution

The Human Tumor Atlas Network (HTAN) stands at the forefront of cancer research, representing a groundbreaking initiative funded by the National Cancer Institute (NCI) as part of the ambitious Cancer Moonshot℠ program. Launched in 2018, HTAN's primary mis

Updated on: November 07,2024

The Human Tumor Atlas Network: Mapping Cancer's Complexity and Evolution

The Human Tumor Atlas Network (HTAN) stands at the forefront of cancer research, representing a groundbreaking initiative funded by the National Cancer Institute (NCI) as part of the ambitious Cancer Moonshot℠ program. Launched in 2018, HTAN's primary mis

Updated on:November 07,2024

Intravesical gemcitabine/docetaxel as an alternative therapy for patients with non-muscle-invasive bladder cancer

by Michael A. O'Donnell and Mohamad Abou Chakra , Medical XpressNMIBC: non-muscle invasive bladder cancer; BCG: Bacillus Calmette-Guérin; Gem: gemcitabine; Doce: docetaxel. Parts of the figure wer

Updated on: April 02,2024

Intravesical gemcitabine/docetaxel as an alternative therapy for patients with non-muscle-invasive bladder cancer

by Michael A. O'Donnell and Mohamad Abou Chakra , Medical XpressNMIBC: non-muscle invasive bladder cancer; BCG: Bacillus Calmette-Guérin; Gem: gemcitabine; Doce: docetaxel. Parts of the figure wer

Updated on:April 02,2024

Developing therapies for treatment-resistant prostate cancer: Small clinical trial shows 40% progression-free survival

byCedars-Sinai Medical CenterGraphical abstract. Credit:Molecular Therapy(2022). DOI: 10.1016/j.ymthe.2022.08.019Investigators from Cedars-Sinai Cancer have identified an investigati

Updated on: December 26,2023

Developing therapies for treatment-resistant prostate cancer: Small clinical trial shows 40% progression-free survival

byCedars-Sinai Medical CenterGraphical abstract. Credit:Molecular Therapy(2022). DOI: 10.1016/j.ymthe.2022.08.019Investigators from Cedars-Sinai Cancer have identified an investigati

Updated on:December 26,2023

Uncovering how air pollution causes lung cancer

byCORDISCredit: AI-generated imageCigarette smoking is the No. 1 risk factor for lung cancer. Exposure to second-hand smoke can also increase the risk of lung cancer. This is what scientists hav

Updated on: December 26,2023

Uncovering how air pollution causes lung cancer

byCORDISCredit: AI-generated imageCigarette smoking is the No. 1 risk factor for lung cancer. Exposure to second-hand smoke can also increase the risk of lung cancer. This is what scientists hav

Updated on:December 26,2023

Men often confused about prostate cancer screening, survey shows

by Ernie MundellA new survey finds the majority of American men believe the first step inprostate cancerscreening is an invasive rectal exam by their doctor.That's not true, but mistak

Updated on: September 27,2024

Men often confused about prostate cancer screening, survey shows

by Ernie MundellA new survey finds the majority of American men believe the first step inprostate cancerscreening is an invasive rectal exam by their doctor.That's not true, but mistak

Updated on:September 27,2024

Structural analysis reveals an unexpected mechanism for a cancer drug

by Tim Stephens,University of California - Santa CruzThe breast cancer drug palbociclib (grey) interacts with its target protein CDK4 (green) in this structural model. Binding of the activator p

Updated on: December 22,2023

Structural analysis reveals an unexpected mechanism for a cancer drug

by Tim Stephens,University of California - Santa CruzThe breast cancer drug palbociclib (grey) interacts with its target protein CDK4 (green) in this structural model. Binding of the activator p

Updated on:December 22,2023

3-D mammography detected 34% more breast cancers in screening

byLund UniversityUsing breast tomosynthesis (3D screening) in the image to the left (one of about 50 thin cross-sectional image slices of the breast), you can see an approximately 1 cm-large tum

Updated on: December 18,2023

3-D mammography detected 34% more breast cancers in screening

byLund UniversityUsing breast tomosynthesis (3D screening) in the image to the left (one of about 50 thin cross-sectional image slices of the breast), you can see an approximately 1 cm-large tum

Updated on:December 18,2023

Unraveling predisposition in bilateral Wilms tumor

bySt. Jude Children's Research HospitalSummary of Proposed Mechanisms for Bilateral Wilms tumor development. Credit:Nature Communications(2023). DOI: 10.1038/s41467-023-43730-0Ch

Updated on: December 30,2023

Unraveling predisposition in bilateral Wilms tumor

bySt. Jude Children's Research HospitalSummary of Proposed Mechanisms for Bilateral Wilms tumor development. Credit:Nature Communications(2023). DOI: 10.1038/s41467-023-43730-0Ch

Updated on:December 30,2023